Ph II Intraperitoneal Paclitaxel + System Therapy in GI Ca w/Peritoneal Carcinomatosis (STOPGAP-B)

NCT07795749 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 55

Last updated 2026-08-31

No results posted yet for this study

Summary

This is a phase II open-label, basket clinical trial to assess the feasibility of systemic and Intraperitoneal chemotherapy in subjects with Gastrointestinal Malignancies with Peritoneal Carcinomatosis. These are subjects who have a proven primary carcinoma of the digestive tract..

Conditions

Esophageal Carcinoma
Gastric Cancer (Diagnosis)
Colorectal Adenocarcinoma
Appendiceal Adenocarcinoma
Small Bowel Adenocarcinoma
Hepatobiliary Carcinoma in Situ

Interventions

DRUG

Paclitaxel Q2W

Given IP-IV, every 2 weeks

DRUG

Paclitaxcel Q3W

Given IP-IV, every 3 weeks

Sponsors & Collaborators

University of California, Irvine
lead OTHER

Principal Investigators

Maheswari Senthil, MD · Chao Family Comprehensive Cancer Center

Study Design

Allocation: NON_RANDOMIZED
Purpose: TREATMENT
Masking: NONE
Model: PARALLEL

Eligibility

Min Age: 18 Years
Sex: ALL
Healthy Volunteers: No

Timeline & Regulatory

Start: 2026-08-04
Primary Completion: 2029-08-31
Completion: 2029-08-31
FDA Drug: Yes

Countries

United States